Infigratinib (FGFR 1/2/3 inhibitor) showed limited efficacy in the entire recurrent glioma patients with the FGFR alterations population but demonstrated a durable response in patients with FGFR1 or FGFR3 point mutations and those with FGFR3-TACC3 fusions [51]. The gene discussed is FGFR3; the disease is central nervous system cancer.